DTM™ spinal cord stimulation shows superior back pain relief in RCT
By Akshay Kedari  Date: 2020-01-22

DTM™ spinal cord stimulation shows superior back pain relief in RCT

Medtronic plc, a Dublin-based medical technology, services, and solutions company, has reportedly announced three-month results from a large, multicenter RCT (randomized controlled trial) demonstrating statistically meaningful (p=0.0009) and improved back pain relief with DTM (Differential Target Multiplexed) SCS (Spinal Cord Stimulation) compared to conventional SCS. Both arms have used the company’s Intellis™ platform.

Reportedly, the three-month outcomes demonstrated 80% of chronic back pain patients treated with DTM registered minimum 50% pain relief, compared to 51% of the patients treated with conventional SCS, as measured by VAS (Visual Analog Scale).

Meanwhile, the RCT showed great pain relief and substantial reductions in leg and back pain with DTM. 63% of patients with back pain treated with DTM showed great pain relief of 80% or more compared to 26% treated with conventional SCS.

All in all, patients treated with DTM demonstrated an average of 74% decrease in back pain compared to 46% with conventional SCS for three months period. Likewise, improvements were noted with DTM for leg pain with a mean decrease of 72% compared to 59% with conventional SCS.

Matt Thomas, General Manager and Vice President of the Stim and Early Interventions business, that is part of the Restorative Therapies Group at Medtronic, said that DTM therapy is the first customized SCS approach purposely created from new scientific concept and demonstrated in an RCT.

The clinical study determines that DTM therapy offers greater efficacy for chronic back pain patients compared to conventional stimulation. Moreover, when combined with Medtronic Intellis, patients could access superior results as displayed in the RCT on an unrivaled simulation platform.

For a record, Medtronic secured DTM therapy as part of its acquisition of Stimgenics declared in early January. DTM therapy is a new and unique programming option to treat patients who are suffering from chronic pain, and is based on years of preclinical research.

Source Credit - http://newsroom.medtronic.com/news-releases/news-release-details/dtmtm-spinal-cord-stimulation-using-medtronic-intellistm

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Embracer Group purchases Saber Interactive in a $525 million deal
Embracer Group purchases Saber Interactive in a $525 million deal
By Akshay Kedari

Embracer Group, a renowned video game holding company and owner of THQ Nordic, has reportedly purchased Saber Interactive, a US games developer, in a deal worth $525 million. Embracer Group had agreed to pay $150 million in both cash as well as stoc...

CDK announces launch of new Repair Order API on Fortellis platform
CDK announces launch of new Repair Order API on Fortellis platform
By Akshay Kedari

CDK Global Inc. has recently announced the launch of the CDK Drive Repair Order API (application programming interface) on Fortellis Automotive Commerce Exchange™ platform. In order to enable dealers to securely open and edit service repair or...

US expands lawsuit against Huawei with charges of theft & racketeering
US expands lawsuit against Huawei with charges of theft & racketeering
By Akshay Kedari

The United States Department of Justice has recently expanded its lawsuit against Huawei, a Chinese multinational tech company. The new charges against the company alleged activities carried out by Huawei such as violating partnership terms with U.S....

ALX Oncology raises $105 million in Series C financing for CD47 trials
ALX Oncology raises $105 million in Series C financing for CD47 trials
By Akshay Kedari

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capit...

VELO3D-Honeywell unite to qualify Sapphire system for aircraft parts
VELO3D-Honeywell unite to qualify Sapphire system for aircraft parts
By Akshay Kedari

VELO3D, a metal Additive Manufacturing (AM) solutions provider, has recently announced its partnership with Honeywell Aerospace, an aircraft engines and avionics manufacturer. The partnership was formed to qualify VELO3D’s Sapphire 3D printing ...